MedPath

Dimerix Advances Kidney Disease Trial with Key Endpoint Validation

• Dimerix's PARASOL working group analysis supports using eGFR and proteinuria as key endpoints for FDA approval of kidney disease treatments. • The ongoing ACTION3 Phase 3 trial by Dimerix is gathering data on eGFR and proteinuria, potentially accelerating market approval. • Dimerix has appointed Dr. Laura Mariani, a nephrologist, to its Medical Advisory Board, strengthening its expertise in kidney disease.

Dimerix Limited (AU:DXB) has announced encouraging results from the PARASOL working group's analysis, reinforcing the use of estimated glomerular filtration rate (eGFR) and proteinuria as crucial endpoints for securing FDA approval in kidney disease therapies. This development is particularly significant as Dimerix's ACTION3 Phase 3 clinical trial is actively collecting data on these endpoints.
The focus on eGFR and proteinuria aligns with regulatory expectations, potentially streamlining the path to market approval for new kidney disease treatments. The ACTION3 trial's design allows for the collection of comprehensive data that could demonstrate the efficacy of Dimerix's therapeutic approach.
To further bolster its expertise, Dimerix has appointed Dr. Laura Mariani, a respected nephrologist, to its Medical Advisory Board. Dr. Mariani's insights and experience in kidney disease management will be invaluable as the company progresses through the clinical trial and regulatory processes.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Dimerix Licenses Phase 3 FSGS Drug DMX-200 to FUSO Pharma for ¥10.5 Billion

Dimerix has granted FUSO Pharmaceutical Industries exclusive rights to develop and commercialize DMX-200 in Japan for focal segmental glomerulosclerosis (FSGS).
The agreement includes an upfront payment of ¥300 million to Dimerix, with potential milestone payments reaching up to ¥9.8 billion, plus royalties.

Dimerix's Phase 3 Trial of DMX-200 for FSGS Completes Part 2 Recruitment, Interim Analysis Expected in August 2025

Dimerix has completed the randomization of the first 144 patients in its ACTION3 Phase 3 trial of DMX-200 for Focal Segmental Glomerulosclerosis (FSGS).
A blinded interim analysis of the initial patient cohort is scheduled for August 2025 to assess statistical powering and confirm study continuation.

Dimerix Partners with NEPTUNE to Accelerate FSGS Trial Recruitment

Dimerix collaborates with the University of Michigan’s NEPTUNE network to boost recruitment for its ACTION3 Phase 3 trial targeting focal segmental glomerulosclerosis (FSGS).
The partnership leverages NEPTUNE's precision medicine platform to identify and refer suitable patients for the trial, potentially speeding up enrollment.

PARASOL Workshop Suggests Broader Proteinuria Endpoints for FSGS Drug Approval

The PARASOL working group presented data at the American Society of Nephrology meeting, confirming the correlation between eGFR improvement and reduced risk of end-stage kidney disease.
Higher proteinuria thresholds (0.7 g/g to 1.5 g/g) have shown significant benefit in reducing the risk of renal failure progression in FSGS patients.

Dimerix Partners with UK National Registry to Accelerate ACTION3 Trial for FSGS

Dimerix collaborates with the UK's National Registry of Rare Kidney Diseases (RaDaR) to enhance patient recruitment for the ACTION3 Phase 3 trial.
RaDaR, the largest kidney registry globally, will identify and contact suitable FSGS patients in the UK for potential trial participation.

Dimerix's First Patient Completes Phase 3 Trial and Enters DMX-200 Open Label Extension Study for Kidney Disease

Dimerix has enrolled the first patient into the Open Label Extension (OLE) study for its kidney disease drug candidate DMX-200 after completing the ACTION3 Phase 3 clinical trial.
The OLE study allows patients who have successfully completed the ACTION3 Phase 3 clinical trial to start or continue a two-year treatment of DMX-200 in an unblinded setting.

Capricor's Deramiocel Shows Sustained Benefits in Duchenne Muscular Dystrophy

Capricor Therapeutics' deramiocel demonstrated a 47% reduction in disease progression in skeletal muscle over three years in DMD patients.
The therapy also showed improvements in cardiac function, particularly in patients with higher ejection fractions at baseline.

Pfizer's DMD Gene Therapy Fails to Meet Primary Endpoint in Phase III Trial

Pfizer's fordadistrogene movaparvovec gene therapy for Duchenne muscular dystrophy (DMD) did not meet the primary endpoint in the Phase III CIFFREO study.
The study, involving patients aged 4-8, assessed motor function improvement using the North Star Ambulatory Assessment (NSAA) scale after one year.

Dimerix's DMX-200 Shows Promise in Phase 3 Trial for Rare Kidney Disease FSGS

Dimerix Limited's DMX-200 demonstrates successful interim results in a Phase 3 trial for Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease.
The trial included 72 patients and showed potential in treating FSGS, which currently has no approved drugs globally, marking a significant advancement.

Reference News

[1]
Dimerix Announces Key Developments in Kidney Disease Trials | Markets Insider
markets.businessinsider.com · Oct 28, 2024

Dimerix Limited (AU:DXB) announced promising results from the PARASOL working group’s analysis, supporting eGFR and prot...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy